AgroAmerica Supports Higher Education to Help Reduce Migration in Latin America
24.3.2021 14:00:00 EET | Business Wire | Press release
The Agribusiness food company, AgroAmerica, is sponsoring the 100K Innovation Fund grant competition for higher education projects aimed at universities in The United States, Central America and the Dominican Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005218/en/
The 100,000 Strong in the Americas Innovation Fund Grant Competition for higher education, promoted by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala, and the NGO Partners of the Americas, aims to impulse education initiatives through innovative models of academic training and student exchange programs between the United States and Central America & Dominican Republic, beginning in January 2022. Institutions of higher education in the United States and Guatemala, El Salvador, Honduras, Costa Rica, Panama, Belize, Nicaragua, and the Dominican Republic are invited to submit their 100K grant proposals to Partners of the Americas at 100kstrongamericas.org/grants before August 2, 2021. (Photo: Business Wire)
The 100K Innovation Fund New Grant Competition is sponsored by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala and the NGO Partners of the Americas. The 100K Fund will be awarded in 12 grants of $25,000 this year to support new higher education projects.
AgroAmerica is the second multinational company in Guatemala to join this public-private initiative. The company's CEO, Fernando Bolaños Valle, said that "it is with great enthusiasm that AgroAmerica joins the State Department as a strategic partner in this regional initiative, in an organic way, because of our shared values; building, through educational programs, a more prosperous future full of hope for our countries… we are convinced that the future of our continent depends on strategic investments like these, which will multiply prosperity for the United States, Guatemala and the region."
Javier Aguirre, corporate director of AgroAmerica, explained that the company donated funds to strengthen local capacities in the areas of climate change, human rights, natural resource management, sustainable agriculture, conservation and reforestation, environmental protection and sustainable businesses.
"The new 100K Strong Americas Innovation Fund partnerships, supported by AgroAmerica and the Department of State, will grow the number of students in the United States, Central America and the Dominican Republic, so working together, they will acquire valuable new skills and knowledge and grow our economies," said Julie Chung, acting assistant secretary of the Bureau of Western Hemisphere Affairs at the U.S. Department of State.
About the 100K Innovation Fund
The 100,000 Strong in the Americas Innovation Fund is the public-private sector collaboration between the Department of State, U.S. embassies and Partners of the Americas to promote a positive agenda for the region by harnessing the power of education.
About AgroAmerica
AgroAmerica is an agribusiness company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. It operates in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. The Company's Corporate Sustainability Strategy aims to generate value and balance between economic growth, natural resource conservation, and the wellbeing of customers, employees, and stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005218/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom